{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Life Science Solutions","title":"Disruptive Trends in Drug and Device Development, with Kymanox President Evan Edwards","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/2474413a\"></iframe>","width":"100%","height":180,"duration":1342,"description":"In this episode of Life Science Solutions, Evan Edwards, President of Kymanox, explores the key trends shaping the life sciences industry in 2025. From groundbreaking advancements in cell and gene therapies to the rise of GLP-1 drugs and the essential scaling of CDMO operations, Evan highlights the innovations driving product development and commercialization. \nKey Takeaways:\nKymanox Growth: The company is expanding its capabilities, workforce, and global footprint, now employing nearly 300 people across the U.S. and Europe.\nIndustry Trends:Cell and Gene Therapy: Emerging targeted treatments are transforming patient outcomes and delivery methods, including potential home-based solutions.\nGLP-1 Drugs: These revolutionary therapies are disrupting healthcare and driving rapid market growth.\nManufacturing Challenges: A rising need for capacity to meet demand for both innovative and traditional therapies.\nArtificial Intelligence: Kymanox is leveraging AI responsibly to enhance drug discovery, manufacturing, and regulatory processes.\nStrategic Focus for 2025:Doubling down on core services like product development, engineering, and regulatory strategy.\nExpanding into strategic services like CMC, CQV, and human factors expertise.\nSupporting clients in reaching critical milestones efficiently, saving time and resources.\nThe Hypervirtual Model: Acting as a trusted co-pilot, Kymanox partners with clients of all sizes, from startups to global pharma giants, to drive innovation and commercialization.\n\nResources and Links:\nLearn more about Kymanox: kymanox.com\nConnect with Kymanox on LinkedIn: Kymanox LinkedIn\n\nAbout Kymanox:\nKymanox has proven, collaborative, end-to-end solutions that help bring life science products to the market – and keep them there. We are a global professional services organization that supports comprehensive drug development with integrated science, engineering, compliance (e.g., QA/RA), and technical project management.  Our work across small and large...","thumbnail_url":"https://img.transistorcdn.com/NJUQJpllzMReojwXSp4vxSqDlm-PIulGozVxmRVQnJE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yOGM2/NjIwZTU1YjljMDM5/ZGRhMWZhODQ2OTAx/NjliZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}